Strong Xarelto Label Warnings Lead To Another Jury Win For Bayer And Janssen

Philadelphia jurors find that warnings of bleeding risk with Xarelto are adequate, giving companies 5-0 litigation score; sixth trial in June.

court house

Bayer Corp. and Janssen Pharmaceuticals Inc. seem to have the best defense against product liability suits claiming they did not provide adequate warning that Xarelto (rivaroxaban) increases the risk of bleeding: labeling that repeatedly specifies the risk.

In the fifth case to go to trial, Russell v. Janssen, jurors in a state court case in Philadelphia issued...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet